Post a Free Blog

Submit A Press Release

At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessEarly Use of Camizestrant Cuts Progression Risk by 56 percent in HR+/HER2–...

Early Use of Camizestrant Cuts Progression Risk by 56 percent in HR+/HER2– Breast Cancer

Add to Favorite
Added to Favorite


Treating women with hormone receptor–positive, HER2-negative breast cancer using AstraZeneca’s (NASDAQ: AZN) experimental oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of resistance to standard therapies halved the risk of disease progression or death. Presented at ASCO 2025, this landmark trial employed a liquid biopsy to guide therapy changes before tumor growth was visible on scans.
Trial Design and Patient Population

Patient cohort: 3,256 women with advanced HR+/HER2– breast cancer

Prior therapy: ≥6 months on aromatase inhibitors plus a CDK4/6 inhibitor (e.g., Novartis’s Kisqali, Pfizer’s Ibrance, Eli Lilly’s Verzenio)

Randomization:

Early switch to camizestrant upon detecting ESR1 mutations in circulating tumor DNA (ctDNA)

Continue standard endocrine ± CDK4/6 inhibitor until radiographic progression

Liquid Biopsy–Guided Intervention

What is a liquid biopsy? A blood test detecting tumor-derived mutations (e.g., ESR1) enabling oncologists to identify resistance prior to scan-detectable progression.

Rationale: By the time imaging shows progression, the tumor has often acquired multiple resistance mechanisms; earlier intervention can “stay ahead of the curve.” (Dr. Eleonora Teplinsky, ASCO expert).

Key Efficacy Results

Primary endpoint: Progression-free survival (PFS) or death

Outcome: 56% reduction in risk of progression or death (HR = 0.44) for the early-switch arm versus standard care.

Median PFS:

Early-switch (camizestrant): Not yet reached at interim analysis

Control arm: ~8.3 months (post–cdrK4/6 inhibitor progression)

Dr. Teplinsky emphasized, “When patients progress on scans, we’re already behind. An early switch allows doctors to essentially stay ahead of the curve.”
Implications for Clinical Practice

Paradigm Shift:

If approved, camizestrant could become the first SERD backed by liquid-biopsy guidance, initiating therapy changes before radiographic progression.

Similar strategies may apply to other targeted agents as ctDNA assays gain regulatory and payer support.

Patient Selection:

ESR1 mutations on ctDNA trigger the switch.

Prospective monitoring with periodic liquid biopsies (e.g., every 8–12 weeks) becomes standard in post–CDK4/6 settings.

Treatment Sequencing:

Following aromatase inhibitor + CDK4/6 inhibitor, early camizestrant may delay progression compared to waiting for imaging-confirmed resistance.

Subsequent lines could include PI3K or mTOR inhibitors, based on evolving mutation profiles.

Camizestrant’s Position in AZN’s Oncology Portfolio
AstraZeneca’s oncology franchise is undergoing rapid expansion. To gauge how critical camizestrant could be to AZN’s growth trajectory—and to see how much revenue streams currently derive from breast cancer drugs—investors can review segment revenues via the Revenue Product Segmentation API, which breaks down AZN’s sales by product class, including targeted oncology therapies.
Financial and Credit Context

AZN’s balance sheet: Strong cash generation and investment capacity support late-stage R&D spend.

Credit profile: Given AstraZeneca’s robust pipeline and diversified revenue base, AZN maintains an investment-grade rating. Track real-time updates on AstraZeneca’s credit metrics via the Company Rating API to see how pipeline successes translate into credit stability.

Broader Impact on HR+/HER2– Treatment Landscape

Liquid Biopsy Adoption: Widespread use may expand beyond ESR1 monitoring to include PIK3CA and other actionable mutations.

SERD Competition: Other oral SERDs (e.g., elacestrant) are also under evaluation; camizestrant’s early-switch data give it a potential edge.

Payor Considerations: Demonstrating PFS benefit without waiting for radiographic progression could justify earlier reimbursement—shaping guidelines and insurance coverage.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Nordic American Tankers Ltd (NYSE:NAT) Financial Overview and Insider Confidence

Earnings Forecast: Analysts predict an EPS of $0.01 and...

Sunnova Energy Corporation’s Financial Challenges and Market Position

Sunnova Energy Corporation, trading on the NYSE under the...

Semtech Corporation (NASDAQ: SMTC) Overview: A Semiconductor Industry Player

The consensus price target for Semtech Corporation (NASDAQ: SMTC)...

Donaldson Company, Inc. (NYSE: DCI) Surpasses Earnings and Revenue Estimates

Donaldson Company, Inc. (NYSE:DCI) reported earnings per share (EPS)...